Why Boston Scientific Corporation, Regeneron Pharmaceuticals, Inc., and Vertex Pharmaceuticals Incorporated Are Today’s 3 Worst Stocks

The worst performers in the stock market on any given day usually exhibit some degree of diversity, if nothing else. One stock will hail from the tech sector, another laggard will represent the energy area, and so on. Alas, no such diversity was present on Tuesday: Boston Scientific Corporation (NYSE: BSX  ) , Regeneron Pharmaceuticals, (NASDAQ: REGN  ) , and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX  ) , today's three worst stocks, all come from the health-care sector. Fighting off this sector-specific sickness, the S&P 500 Index (SNPINDEX: ^GSPC  ) was able to tack on four points, or 0.2%, to end at 1,941.

Shares of the medical device company Boston Scientific shed 2.5% on Tuesday after identifying two possible uses for its cash on hand. It plans on either returning cash to shareholders through share buybacks, or using its dough for mergers and acquisitions. I'm not sure why this came as such a shock to investors, because both strategies are legitimate and frequently employed by corporate America. On top of that, Boston Scientific held less than $200 million in hard cash on hand at the end of last quarter, making it tough for the $16 billion company to move the needle with its cash alone.

Elsewhere in health care, biotech Regeneron Pharmaceuticals lost 1.9% in trading today. Biotech was the worst-performing industry within the health-care sector on Tuesday, and Regeneron shareholders were victims of that trend. Much of the company's potential hinges on the continued success of Eylea, an injection that treats age-related macular degeneration. The blockbuster success of the drug has helped to catapult Regeneron sales from $445 million a year in 2011 to $2.1 billion last year.

Cystic fibrosis treatment kalydeco has been a big winner for Vertex. Source: Vertex Pharmaceuticals

Lastly, shares of Vertex Pharmaceuticals stumbled 1.8% today. The stock is continuing a troublesome trend: it finished as the S&P 500's worst performer yesterday after a Wall Street analyst essentially nixed the possibility that phase III trials for new cystic fibrosis treatments would turn out well. Investors are inclined to believe the Bernstein analyst, who just returned from a cystic fibrosis conference in Sweden, where he spoke to pessimistic scientists. Invoke pessimistic foreign scientists at an obscure conference and investors will give you a podium -- especially in the health-care sector.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier, and more accurately, than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not only how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you'll need to read The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2998168, ~/Articles/ArticleHandler.aspx, 9/2/2015 7:50:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

John Divine

Fool since 2012, unique fingerprints since birth. Age 7: Put lifetime savings ($18.37!) in the bank, became disillusioned with low interest, and a fascination with the stock market was born.

Today's Market

updated Moments ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 4:36 PM
^GSPC $1948.86 Up +35.01 +1.83%
S&P 500 INDEX CAPS Rating: No stars
BSX $16.51 Up +0.42 +2.61%
Boston Scientific… CAPS Rating: ***
REGN $518.78 Up +22.36 +4.50%
Regeneron Pharmace… CAPS Rating: ***
VRTX $129.00 Up +4.96 +4.00%
Vertex Pharmaceuti… CAPS Rating: ***